Ducol Organics' Q2 profit fell 46% sequentially as standalone revenue dropped sharply and debt from recent acquisitions weighed on margins.
Ducol Organics reported a sharp decline in both revenue and profit for Q2 FY27, with profit falling 46% from the previous quarter. The drop comes despite recent acquisitions, as higher interest costs and lower other income squeezed margins.
Ducol Organics is navigating a transition, using acquisitions to build a specialty chemicals platform beyond its core pigment business. The September quarter shows that shift is still costly, with the old business slowing and the new one yet to deliver full operating leverage.
Standalone revenue fell 32% from the March quarter to ₹48.71 crore, pulling net profit down 46% to ₹2.15 crore. Compared to last year, sales were down 25% and profit fell 28%. The net profit margin slipped to 4.4%, down 120 basis points sequentially.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|
| Revenue (₹ Cr) | 48.71YoY -25% | 65.00 |
| Profit (₹ Cr) | 2.15YoY -28% | 3.00 |
| Net Profit Margin (%) | 4.4YoY -4.3% | 4.6 |
A sharp 74% drop in other income and a 38% year-on-year jump in interest expense compounded the revenue decline. According to the company's investor presentation cited by Arthneeti, the higher finance cost of ₹1.79 crore for the half-year is due to acquisition-related borrowings. Long-term borrowings rose from ₹23.11 crore in March to ₹40.21 crore in September.
The weak standalone print contrasts with a stronger consolidated picture, which includes recent buys Bitumag and Xchem. Management, in its maiden earnings call summarized by ALFA Finder, said H1 consolidated revenue was ₹112.26 crore, up 74% year-on-year and driven by these acquisitions. The call summary notes the acquired units currently deliver 9-10% EBITA margins, below the 12-15% target.
With the new businesses running at just 30-35% capacity, the path to better margins relies on utilization and cross-selling. Management targets at least a 10.5% consolidated EBITDA margin for FY27, as reported by Sovrenn. They see no need for major new capacity, expecting growth from better use of existing plants.
Live Chart
· DUCOL
(BSE)
ISIN: INE0LZO01015
Key Points
The quarter lays bare the tension in Ducol's strategy. The core business is contracting just as debt-funded acquisitions add cost. The promise is in the long runway of the new units, but the near term is a squeeze. Investors are being asked to fund a transition where the payoff depends entirely on execution—ramping utilization, achieving cross-sales, and managing a higher debt load. The stock's 32% decline over the past year suggests the market is pricing in that execution risk.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.